4D Molecular Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities
4D Molecular Therapeutics, Inc. (FDMT) reported Increase (Decrease) in Accrued Liabilities of $2.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-13
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.54M, a 110.42% increase year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.12M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $2.37M.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $4.98M, a 38.53% decline year-over-year.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $8.15M, a 24.95% increase from fiscal 2024.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $6.52M, a 93.53% increase from fiscal 2023.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $3.37M, a 35.65% increase from fiscal 2022.
- 4D Molecular Therapeutics, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $2.48M, a 260.67% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $6.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $2.42M 10-Q · filed 2026-08-13 | $4.79M derived: sum of 3 quarters · filed 2026-08-13 | $9.78M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | -$4.12M 10-Q · filed 2026-05-07 | -$1.75M derived: sum of 2 quarters · filed 2026-05-07 | $3.23M derived: sum of 3 quarters · filed 2026-05-07 | $6.34M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $7.35M derived: sum of 2 quarters · filed 2026-03-18 | $10.46M derived: sum of 3 quarters · filed 2026-08-13 | $8.15M 10-K · filed 2026-03-18 | |
| 2025-09-30 | $4.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $8.09M derived: sum of 2 quarters · filed 2026-08-13 | $5.78M 10-Q · filed 2025-11-10 | $3.41M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-06-30 | $3.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $798.00K 10-Q · filed 2026-08-13 | -$1.57M derived: sum of 3 quarters · filed 2026-08-13 | $6.54M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2025-03-31 | -$2.31M 10-Q · filed 2026-05-07 | -$4.68M derived: sum of 2 quarters · filed 2026-05-07 | $3.43M derived: sum of 3 quarters · filed 2026-05-07 | $6.60M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | $5.74M derived: sum of 2 quarters · filed 2026-03-18 | $8.91M derived: sum of 3 quarters · filed 2026-03-18 | $6.52M 10-K · filed 2026-03-18 | |
| 2024-09-30 | $8.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $11.28M derived: sum of 2 quarters · filed 2025-11-10 | $8.89M 10-Q · filed 2025-11-10 | $10.89M derived: sum of 4 quarters · filed 2025-11-10 | |
| 2024-06-30 | $3.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $785.00K 10-Q · filed 2025-08-11 | $2.78M derived: sum of 3 quarters · filed 2025-08-11 | $6.39M derived: sum of 4 quarters · filed 2025-08-11 | |
| 2024-03-31 | -$2.39M 10-Q · filed 2025-05-08 | -$392.00K derived: sum of 2 quarters · filed 2025-05-08 | $3.22M derived: sum of 3 quarters · filed 2025-05-08 | $4.38M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $5.61M derived: sum of 2 quarters · filed 2025-02-28 | $6.77M derived: sum of 3 quarters · filed 2025-02-28 | $3.37M 10-K · filed 2025-02-28 | |
| 2023-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $4.77M derived: sum of 2 quarters · filed 2024-11-13 | $1.37M 10-Q · filed 2024-11-13 | $3.20M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $1.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.24M 10-Q · filed 2024-08-08 | -$416.00K derived: sum of 3 quarters · filed 2024-08-08 | $668.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$3.40M 10-Q · filed 2024-05-09 | -$1.57M derived: sum of 2 quarters · filed 2024-05-09 | -$490.00K derived: sum of 3 quarters · filed 2024-05-09 | $162.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $2.91M derived: sum of 2 quarters · filed 2024-02-29 | $3.56M derived: sum of 3 quarters · filed 2024-02-29 | $2.48M 10-K · filed 2024-02-29 | |
| 2022-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $1.74M derived: sum of 2 quarters · filed 2023-11-09 | $662.00K 10-Q · filed 2023-11-09 | $1.20M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $652.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$422.00K 10-Q · filed 2023-08-09 | $113.00K derived: sum of 3 quarters · filed 2023-08-09 | $1.17M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | -$1.07M 10-Q · filed 2023-05-11 | -$539.00K derived: sum of 2 quarters · filed 2023-05-11 | $519.00K derived: sum of 3 quarters · filed 2023-05-11 | $1.06M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $535.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.59M derived: sum of 2 quarters · filed 2023-03-15 | $2.14M derived: sum of 3 quarters · filed 2023-03-15 | $689.00K 10-K · filed 2023-03-15 | |
| 2021-09-30 | $1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $1.60M derived: sum of 2 quarters · filed 2022-11-08 | $154.00K 10-Q · filed 2022-11-08 | $181.00K derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $546.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$904.00K 10-Q · filed 2022-08-11 | -$877.00K derived: sum of 3 quarters · filed 2022-08-11 | -$3.02M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$1.45M 10-Q · filed 2022-05-12 | -$1.42M derived: sum of 2 quarters · filed 2022-05-12 | -$3.57M derived: sum of 3 quarters · filed 2022-05-12 | -$157.00K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$2.12M derived: sum of 2 quarters · filed 2022-03-28 | $1.29M derived: sum of 3 quarters · filed 2022-03-28 | $1.90M 10-K · filed 2022-03-28 | $1.90M 10-K · filed 2021-03-25 |
| 2020-09-30 | -$2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.27M derived: sum of 2 quarters · filed 2021-11-10 | $1.87M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $3.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $4.02M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $606.00K 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | $3.84M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Entera Bio Ltd. (ENTX) | $0.485B |